Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002528907 | SCV000765740 | likely pathogenic | Aicardi-Goutieres syndrome 1; Chilblain lupus 1; Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations | 2017-09-24 | criteria provided, single submitter | clinical testing | This variant is not present in population databases (ExAC no frequency). This sequence change results in a premature translational stop signal in the TREX1 gene (p.Lys277*). While this is not anticipated to result in nonsense mediated decay, it is expected to delete the last 38 amino acids of the TREX1 protein. This variant has not been reported in the literature in individuals with TREX1-related disease. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Different truncating variants downstream from this codon (c.850dupA, c.858dupG, 830_833dup) have been reported in multiple individuals affected with retinal vasculopathy with cerebral leukodystrophy (HERNS syndrome) (PMID: 17660820, 26691497). Experimental studies have shown that these truncated proteins retain exonuclease activity but lose normal perinuclear localization (PMID: 17660820). This suggests that the C-terminal sequence is critical for TREX1 protein function. |